Dassault Systèmes (EPA: DSY) Shares Rise After Q2 Earnings Beat and Up to $2 Billion ArisGlobal AI Deal

Dassault Systèmes reported solid Q2 2026 results on July 23, alongside a major acquisition announcement. The French software maker posted total revenue of €1.56 billion, up 4% in constant currency. Non-IFRS diluted EPS climbed 8% to €0.31, while operating margin expanded to 30%. 

Dassault Systèmes also unveiled a deal to acquire life sciences software firm ArisGlobal for up to $2 billion, deepening its push into AI-driven healthcare compliance.

Q2 Revenue and Margins Beat Expectations

Dassault Systèmes delivered broad-based growth across its core software segments during the second quarter. Subscription revenue rose 8%, while 3DEXPERIENCE and cloud software revenue each jumped 14%.

• Annual Run Rate reached €4.44 billion, up 6% year-over-year.
• Recurring revenue now makes up 81% of total software revenue.
• First-half operating cash flow grew 11% to €1.24 billion.

Manufacturing Industries drove much of the cloud and platform growth this quarter. Free cash flow rose 13% year-over-year, with cash conversion reaching 134%.

Dassault Systèmes : bond de 28% du bénéficit net au S1 📈

"Ce sont des résultats solides portés par la bascule du mouvement vers l'abonnement. Et ce trimestre là, notre croissance des abonnements est de +8%."

💬 Pascal Daloz, PDG de Dassault Systèmes pic.twitter.com/CtlTRmOpYA

— BFM Business (@bfmbusiness) July 23, 2026

Balance Sheet Strength Sets Up the ArisGlobal Deal

Dassault Systèmes entered its acquisition announcement from a position of financial strength. Net financial position stood at €2.28 billion as of June 30, 2026.

• Cash and cash equivalents totaled €5.66 billion at quarter-end.
• The company issued €1.0 billion in bonds during June 2026 to refinance its credit facility.
• FY26 non-IFRS revenue guidance stands at €6,296 to €6,416 million, implying 3-5% growth.

Management confirmed its full-year EPS guidance of €1.30 to €1.34, unchanged despite the new acquisition spending.

Dassault Systèmes Targets Life Sciences With ArisGlobal

Dassault Systèmes will acquire ArisGlobal in an all-cash deal worth $1.8 billion, with up to $200 million in additional earnout payments. The transaction targets a compliance market forecast to hit $7.5 billion by 2030.

• ArisGlobal’s platform processes more than 12 million patient safety reports annually.
• The company serves over 200 Life Sciences customers, including half of the world’s top 50 biopharma firms.
• ArisGlobal is expected to generate $175 million in revenue during 2026.

The deal is funded entirely from Dassault Systèmes’ existing cash reserves, with closing targeted for the second half of 2026.

Why This Deal Matters for Dassault Systèmes’ AI Strategy

This acquisition builds directly on Dassault Systèmes’ existing Medidata clinical trials business within Life Sciences. Combining ArisGlobal’s safety-reporting data with Medidata creates a unified intelligence layer.

• Management expects the deal to be accretive to both revenue growth and EPS in Year 1.
• ArisGlobal also serves biotech, medtech, and global health authorities beyond core biopharma clients.
• The combined platform aims to connect molecule, patient, and real-world outcome data.

Regulatory approval remains the key condition before the transaction can officially close later this year.

How the Market Is Reading the News

Dassault Systèmes shares closed at €17.76 on July 22, ahead of the earnings and acquisition news. That’s well below the stock’s 52-week high of €33.16, hit in July 2025.

• The stock’s 52-week low sits at €15.82, touched in February 2026.
• Berenberg analyst Nay Soe Naing raised his price target to €24 from €23, maintaining a Buy rating.
• The average 12-month analyst target across 20 brokerages stands at €22.82, implying meaningful upside.

Consensus analyst sentiment currently sits at “Hold,” reflecting a wait-and-see stance following February’s sharp single-day selloff.

Dassault Systèmes agrees to acquire ArisGlobal, a US supplier of software to the life sciences industry, from Nordic Capital for ~$2B, set to close in H2 2026 (Adrià Calatayud / Wall Street Journal)

(Visit Techmeme dot com for the link and full context!)

— Techmeme (@Techmeme) July 23, 2026

The Road Ahead

Dassault Systèmes’ Q2 results confirm steady execution on its core software business, with cloud and subscription revenue both accelerating past company-wide averages. The ArisGlobal acquisition signals management’s confidence in expanding beyond CAD and PLM into regulated healthcare data, a segment with clear structural growth tailwinds through 2030. 

Competing against Autodesk, PTC, and Siemens in industrial software, Dassault Systèmes is betting that deeper Life Sciences integration differentiates its AI platform. Investors will likely watch regulatory approval timelines and integration progress with ArisGlobal as the next real catalyst for the stock.

Disclaimer:

The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.